Tavexia Lifecare approves ₹67.19 cr Meyonex deal in 2026

What the board approved and why it matters

Tavexia Lifecare Limited has approved the acquisition of up to 60% of the equity share capital of Meyonex Pharmaceuticals Limited, an unlisted public company. The board decision was taken at its meeting held on October 7, 2026. The proposed acquisition will be executed through a fresh share subscription in Meyonex rather than a purchase from existing shareholders. Tavexia has disclosed a total cash consideration of ₹67.19 crore for the stake. The company said the transaction is intended to expand its presence in the pharmaceutical sector. The approval sets the transaction framework, but completion remains subject to a set of conditions and approvals. Investors are also watching the funding plan because the board has provided in-principle approval for a fundraise to finance the deal.

Deal structure: fresh shares, control, and cash payment

The acquisition is structured as a subscription to 2,09,97,180 fresh equity shares to be issued by Meyonex to Tavexia Lifecare. The issue price is ₹32 per share. Based on the disclosed terms, the total consideration works out to ₹67.19 crore (also reported as ₹67,19,09,760). Tavexia has stated the payment mode will be entirely in cash. Because the shares are newly issued, the transaction expands Meyonex’s equity base and results in Tavexia becoming the majority shareholder upon allotment. After completion, Tavexia will hold a controlling 60% stake, while the existing shareholders of Meyonex will retain the remaining 40%. The company has also said the acquisition may be completed in one or more tranches.

Post-allotment shareholding and equity base

Tavexia’s disclosures provide a clear split of shares before and after the proposed allotment. Meyonex’s existing paid-up equity share count is stated at 1,39,98,120 shares, which will represent 40% post-transaction. The fresh issuance of 2,09,97,180 shares to Tavexia will represent 60% post-transaction. After the proposed allotment, the total equity shares of Meyonex are expected to stand at 3,49,95,300 shares. This structure indicates a control transaction achieved via dilution at the target level rather than a secondary stake purchase. For Tavexia, the key outcome is the ability to consolidate control subject to approvals and definitive documentation. For Meyonex’s current shareholders, the result is retention of a minority holding after a capital increase.

Conditions precedent: approvals and definitive agreements

Tavexia has highlighted that the acquisition is subject to necessary statutory, regulatory, governmental, contractual, and other approvals. It also requires shareholder approval of Tavexia Lifecare wherever applicable. The company has stated that definitive agreements must be executed and terms and conditions in those agreements must be fulfilled, including applicable conditions precedent. Until these steps are completed, the approval remains an in-principle corporate action rather than a completed investment. Tavexia’s disclosures also indicate that regulatory approvals are pending as the company proceeds with definitive documentation. The company has positioned the transaction as not being with promoter group companies. It has also disclosed that the acquisition does not constitute a slump sale.

Timeline: from evaluation to final board approval

The sequence of disclosures shows the deal moving through internal evaluation into a formal approval framework. Tavexia earlier authorised a preliminary evaluation of the proposed acquisition of up to 60% of Meyonex, empowering two directors to conduct due diligence, valuation, and negotiations. Separately, the company had indicated that its board would meet on October 7, 2026 to deliberate on the proposed acquisition and review progress on due diligence and negotiations. On October 7, 2026, the board reviewed and approved the valuation report and due diligence report in relation to the proposed acquisition. Following that review, it approved the proposed acquisition structure through subscription to fresh equity shares. This progression is important because it shows the decision followed internal reports rather than being announced without a documented process.

Who is Meyonex Pharmaceuticals

Meyonex Pharmaceuticals Limited is described as an unlisted public company operating in the pharmaceuticals industry. The company’s date of incorporation is stated as January 17, 2015. Tavexia has also described Meyonex as an Indian company, and one disclosure referenced it as being based in Thane, Maharashtra. As an unlisted entity, its financial and operating details are primarily available through what the acquirer has disclosed. Tavexia’s stated rationale for the acquisition is to expand its presence in the pharmaceutical sector. Beyond that stated intent, Tavexia has not disclosed a detailed integration plan, product roadmap, or specific synergy targets in the information provided.

Financial snapshot disclosed for Meyonex

Tavexia’s disclosures include turnover figures for Meyonex across two financial years. Meyonex reported turnover of around ₹13.32 crore in FY2024 and around ₹10.79 crore in FY2025. The figures highlight that the target’s revenue base, as disclosed, is relatively modest compared with the acquisition consideration. Tavexia has not disclosed profitability figures, margins, or cash flow numbers for Meyonex in the information provided. It has also not disclosed the valuation basis beyond stating that the board reviewed the valuation report. Because Meyonex is unlisted, investors typically rely on the acquirer’s disclosures for such context, and in this case those details remain limited.

Funding plan: in-principle approval for a raise

Alongside the acquisition approval, Tavexia’s board granted in-principle approval for a fundraising exercise to finance the transaction. The company has indicated possible routes including a preferential issue or a rights issue. It has also mentioned instruments such as equity shares, warrants, debentures, or other debt securities. Importantly, Tavexia has said that the quantum, price, and timing of the fundraising will be decided later. That means the capital structure impact is not yet quantified, but the company has signalled that external funding will likely be required. One disclosure also noted that the proposed acquisition value exceeds Tavexia’s TTM revenue of ₹32 crore and net worth of ₹43 crore, reinforcing why financing decisions may be central to investor assessment.

Market impact: what investors will track next

The immediate market relevance comes from three moving parts: completion conditions, fundraising execution, and disclosure depth. First, the transaction is subject to shareholder, statutory, and regulatory approvals, plus definitive documentation, which can affect timelines. Second, the planned fundraise introduces potential dilution and pricing sensitivity, depending on whether it is done via preferential allotment, rights issue, or debt-linked instruments. Third, while Tavexia has shared deal mechanics and turnover numbers for the target, it has not disclosed the profitability of Meyonex or the valuation methodology behind the ₹32 per share issue price. Investors typically track these variables for unlisted acquisitions because they shape whether the acquisition is accretive, neutral, or a balance-sheet strain. Tavexia has also stated the transaction may be completed in tranches, so progress could come in stages rather than a single closing date.

Analysis: what the transaction signals for Tavexia

This is a control acquisition via primary capital infusion into an unlisted pharmaceutical company. Structuring the deal as fresh issuance means the funds go into Meyonex rather than to selling shareholders, which can be relevant for capacity building, working capital, or expansion, depending on how Meyonex uses the proceeds. The board’s review of valuation and due diligence reports indicates the company followed a formal approval process, but investors still lack details on profitability, completion timelines, and the definitive agreement terms. The parallel in-principle approval for fundraising highlights that capital allocation and funding structure will be as important as the acquisition itself. Until the company announces the fundraising route and secures pending approvals, the transaction remains conditional. The next set of disclosures, if any, will likely determine how the market frames both the opportunity and the financing risk.

Conclusion

Tavexia Lifecare’s board has approved an all-cash ₹67.19 crore subscription to acquire 60% of Meyonex Pharmaceuticals at ₹32 per share, with completion subject to approvals and definitive agreements. The company has also cleared an in-principle plan to raise funds to finance the acquisition, with details to be decided later.